Faculty: Philip Seeman, MD, PhD

Philip Seeman, MD, PhDPhilip Seeman, MD, PhD
Professor Emeritus

General Research Area: Neuropharmacology
Transmitter Receptors and Genes in Brain in Health and Disease

Not taking new graduate students

Selected Publications:

Seeman P. All psychotic roads lead to increased D2High dopamine receptors. A perspective. Clin. Schizophrenia and Related Psychoses; Jan., 2008: 351-355.

Willeit M, Ginovart N, Graff A, Rusjan P, Vitcu I, Houle S, Seeman P, Wilson AA and Kapur S. First human evidence of d-amphetamine induced displacement of a D2/3 agonist radioligand: A [11C]-(+)-PHNO positron emission tomography study. Neuropsychopharmacology, 2007; Epub Apr. 4.

Seeman, P. Dopamine and Schizophrenia. Scholarpedia. 2007; p. 17210.

Seeman P, Schwarz J, Chen J-F, Szechtman H, Perreault M, McKnight GS, Roder JC, Quirion R, Boksa P, Srivastava LK, Yanai K, Weinshenker D and Sumiyoshi T. Psychosis pathways converge via D2High dopamine receptors. Synapse, 2006; 60:319-346.

Seeman P. Targeting the dopamine D2 receptor in schizophrenia. Expert Opinion on Therapeutic Targets, 2006; 10:515-531.

Seeman P, Weinshenker D, Quirion R, Srivastava L, Bhardwaj SK, Grandy DK, Premont R, Sotnikova T, Boksa P, El-Ghundi M, O’Dowd BF, George SR, Perreault ML, Mannisto PT, Robinson S, Palmiter RD and Tallerico T. Dopamine supersensitivity correlates with D2High states, implying many paths to psychosis. Proc. Nat. Acad. Sci. U.S.A. 2005; 102:3513-3518.

Seeman P. Comment: Diverse psychotomimetics act through a common signaling pathway. Science, 2004; 305:180.

Seeman P. Anti-Parkinson therapeutic potencies correlate with their affinities for dopamine D2High receptors. Synapse, 2004; 61:1013-1018.


Email: philip.seeman@utoronto.ca

Back to Top